Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Inter-Alia To Consider And Approve The Audited (Standalone And Consolidated) Financial Results Of The Company For The Quarter And Year Ended On March 31, 2022

 LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2022 ,inter alia, to consider and approve audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31, 2022
11-05-2022
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayLINCOLN PHARMACEUTICALS LTD. 2CINL24230GJ1995PLC024288 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: NIREN DESAI Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: nirendesai@lincolnpharma.com Name of the Chief Financial Officer: DARSHIT SHAH Designation: CHIEF FINANCIAL OFFICER EmailId: darshit@lincolnpharma.com Date: 25/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
25-04-2022
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Certificate Under Regulation 40 (9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

 Please find enclosed herewith Certificate from the Practicing Company Secretary under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2022.
25-04-2022
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Pursuant to provision of Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the confirmation certificate as received from M/s. Link Intime India Private Limited, Registrar & Share Transfer Agent (RTA) for the Quarter Ended March 31, 2022.
11-04-2022
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Statement Of Investor Complaints For The Quarter Ended March 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NIREN DESAIDesignation :- Company Secretary and Compliance Officer
07-04-2022
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Closure of Trading Window

 Intimation of Closure of Trading Window during the F.Y. 2022-2023.
31-03-2022
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajanikant Gulabdas Patel
23-03-2022
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajanikant Gulabdas Patel
14-03-2022
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shardaben Gulabdas Patel
14-03-2022
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajanikant Gulabdas Patel
14-03-2022
Next Page
Close

Let's Open Free Demat Account